CSL Limited ready for China
On Tuesday, CSL Limited (ASX: CSL) announced its decision to acquire 80% of the equity of plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products (Ruide) in China for US $352 million. The transaction will see the company enter the Chinese domestic plasma fractionation market. CSL Limited has demonstrated significant earnings momentum in FY17, and we see this continuing into the new financial year. Shares in CSL Limited closed up 2.9% for the week. We own CSL Limited as a market-driven investment in WAM Leaders.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Matthew has more than 20 years’ experience in the investment industry working as both a portfolio manager and analyst. Prior to joining Wilson Asset Management in 2004, Matthew gained extensive large-cap experience in his previous role within Australian Executor Trustees (now part of Equity Trustees). Matthew is the Lead Portfolio Manager responsible for WAM Leaders Limited and Wilson Asset Management Leaders Fund.
2 stocks mentioned
Matthew has more than 20 years’ experience in the investment industry working as both a portfolio manager and analyst. Prior to joining Wilson Asset Management in 2004, Matthew gained extensive large-cap experience in his previous role within...
Expertise
Matthew has more than 20 years’ experience in the investment industry working as both a portfolio manager and analyst. Prior to joining Wilson Asset Management in 2004, Matthew gained extensive large-cap experience in his previous role within...
Expertise
Comments
Comments
Sign In or Join Free to comment